BRAF KINASE INHIBITORS MARKET ANALYSIS

Regional Analysis

BRAF Kinase Inhibitors Market – Regional Analysis

North America is estimated to hold the dominant position in 2020 in the global BRAF kinase inhibitors market. Increasing number of product approvals by the regulatory authorities is a major factor that propels growth of the North America BRAF kinase inhibitors market. For instance, in July 2020, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive melanoma. The approval is based on results from IMspire150, a multicenter, double-blind, placebo-controlled randomized phase III study.

Moreover, Europe BRAF kinase inhibitors market is also expected to gain momentum over the forecast period. For instance, in September 2018, Pierre Fabre announced that the European Commission (EC) granted marketing authorization for the combination of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. The EC decision is applicable to all 28 European Union (EU) member states and Liechtenstein, Iceland, and Norway.

• North America: U.S. and Canada
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of APAC
• Middle East: GCC, Israel, and Rest of Middle East
• Africa: South Africa, North Africa, and Central Africa